Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice  by Gainetdinov, Raul R et al.
Neuron, Vol. 38, 291–303, April 24, 2003, Copyright 2003 by Cell Press
Dopaminergic Supersensitivity
in G Protein-Coupled Receptor
Kinase 6-Deficient Mice
and GRK5 (Benovic and Gomez, 1993; Premont et al.,
1999). Multiple GRK enzymes (GRK2, GRK3, GRK5, and
GRK6) are found throughout the brain (Gainetdinov et al.,
2000; Erdtmann-Vourliotis et al., 2001), but the relative
physiological importance of each GRK to the regulation
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The catecholamine dopamine plays a critical role in1Howard Hughes Medical Institute Laboratories
2 Department of Cell Biology several brain functions, including movement control,
emotion, and affect (Carlsson, 2001; Greengard, 2001).3 Department of Medicine
4 Department of Biochemistry Physiological responses to dopamine are controlled by
a family of five G protein-coupled dopamine receptorsDuke University Medical Center
Durham, North Carolina 27710 (D1-D5), which are classified into D1-like (D1, D5) and
D2-like (D2, D3, D4) subfamilies based on functional and
pharmacological properties (Grandy and Civelli, 1992;
Schwartz et al., 1993; Seeman and Van Tol, 1994; PicettiSummary
et al., 1997; Missale et al., 1998; Sibley, 1999). Sensitivity
of dopamine receptors to endogenous and exogenousBrain dopaminergic transmission is a critical compo-
ligands is known to be an important modulator of dopa-nent in numerous vital functions, and its dysfunction
mine-related functions in physiology and pathology. Su-is involved in several disorders, including addiction
persensitivity of dopamine signaling has been postu-and Parkinson’s disease. Responses to dopamine are
lated in several brain disorders (Pandey et al., 1977;mediated via G protein-coupled dopamine receptors
Jenner and Marsden, 1987; Kirkpatrick et al., 1992;(D1-D5). Desensitization of G protein-coupled recep-
Singer, 1994; Willner, 1997), including addiction (Nestlertors is mediated via phosphorylation by members of
and Aghajanian, 1997; Nestler, 2001; Hyman and Ma-the family of G protein-coupled receptor kinases
lenka, 2001; Laakso et al., 2002). Particularly, it is be-(GRK1-GRK7). Here we show that GRK6-deficient
lieved that chronic psychostimulant-induced sensitiza-mice are supersensitive to the locomotor-stimulating
tion, an early biochemical and behavioral manifestationeffect of psychostimulants, including cocaine and am-
of cellular plasticity leading to addiction, is associatedphetamine. In addition, these mice demonstrate an
with long-term changes in dopamine receptor respon-enhanced coupling of striatal D2-like dopamine recep-
siveness (Nestler, 2001; Hyman and Malenka, 2001;tors to G proteins and augmented locomotor response
Laakso et al., 2002). Previous in vitro studies have shownto direct dopamine agonists both in intact and in dopa-
that the D1, D2, and D3 dopamine receptors can bemine-depleted animals. The present study indicates
phosphorylated by some GRKs (Tiberi et al., 1996; Itothat postsynaptic D2-like dopamine receptors are
et al., 1999; Kim et al., 2001), but the role of GRK6 inphysiological targets for GRK6 and suggests that this
dopamine receptor regulation has never been investi-regulatory mechanism contributes to central dopa-
gated. Furthermore, no data on physiological significanceminergic supersensitivity.
of receptor regulation or the in vivo specificity of dopa-
mine receptor/GRK interaction are currently available.Introduction
To understand the role of GPCR desensitization
mechanisms in the regulation of dopamine function, weG protein-coupled receptors (GPCRs) are regulated via
have begun to examine mice bearing inactivated GRKactivation-dependent phosphorylation by a family of G
genes for alterations in cocaine responses and dopa-protein-coupled receptor kinases (GRKs) (Premont et
mine receptor properties. In a previous investigation,al., 1995; Pitcher et al., 1998; Penn et al., 2000). This
we found no evidence for dopaminergic supersensitivityprocess, which modulates the coupling state of GPCRs
in mice lacking GRK5 (Gainetdinov et al., 1999). Hereto their G proteins, is critically involved in GPCR desensi-
we report that mice lacking GRK6 are supersensitive totization (Pitcher et al., 1998; Penn et al., 2000). GRK-
locomotor stimulating effects of several psychostimu-phosphorylated receptors bind to an arrestin protein,
lants, display enhanced coupling of D2-like receptorswhich prevents the receptor from activating more G
to their G proteins, and show enhanced behavioral ef-proteins despite the continued binding of agonist
fects of direct dopamine agonists.(Pitcher et al., 1998). Seven distinct GRK genes are
known, named GRK1 through GRK7, that are classified
Resultsinto three distinct groups (Pitcher et al., 1998; Premont
et al., 1999; Penn et al., 2000). GRK6 is a member of the
Generation of GRK6-KO MiceGRK4 subfamily of GRKs, which also contains GRK4
To address the functions of GRK6 in vivo, the GRK6
gene was targeted by homologous recombination in ES
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cells, as shown in Figures 1A–1C. The targeting con-receptor-biol.duke.edu (R.J.L.)
struct introduces into the mouse GRK6 gene two loxP5 Current address: Clinical Research and Development, Glaxo-
SmithKline, Harlow, Essex, United Kingdom. sites, flanking exons 3 through 9, as well as a selection
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Figure 1. Targeted Inactivation of the Mouse GRK6 Gene
(A) Schematic diagram of the wild-type GRK6 locus, the GRK6/lox targeting vector, the integrated targeting construct, and the Cre recombinase-
deleted GRK6 locus (GRK6-KO). GRK6 exons are shown as open boxes and numbered from the first coding exon (Premont et al., 1999). LoxP
sites are shown as filled triangles, and the location of the Southern blot probe as a hatched box. Relevant NheI restriction sites are indicated.
(B) Genotyping of targeted GRK6-KO mice. The wild-type and GRK6-KO loci were distinguished by triplex PCR amplification as described in
Experimental Procedures. The wt GRK6 locus gives a 460 bp band while the GRK6-KO locus gives a 610 bp band, as indicated.
(C) GRK6 protein expression by Western blotting. Membrane proteins from brainstem and striatum (data not shown) of wild-type and GRK6-
KO animals were subjected to immunoblotting using an anti-GRK6 antiserum (Stoffel et al., 1994). GRK6-KO homozygote animals exhibit a
loss of the 68 kDa immunoreactive band compared to wild-type animals (arrow). The 69 kDa band is a nonspecific interaction, since it is
present in GRK5 and GRK4 knockout animals and is not recognized by another GRK6 antiserum (data not shown).
(D) GRK6 is present in striatal neurons expressing DARPP-32. Top left: Immunofluorescence analysis reveals GRK6 immunoreactivity in the
striatal neurons of wt mouse (0.74 from bregma). Top right: Lack of GRK6 immunoreactivity in the striatal neurons of GRK6-KO mouse.
Bottom left: DARPP-32 immunoreactivity in the striatal neurons of wt mouse. Bottom right: GRK6 and DARPP-32 are colocalized in the same
neuronal population in the striatum of wt mouse. GRK6 immunoreactivity was detected using a commercially available anti-GRK6 antibody
(rabbit, 1:50, sc-566, Santa Cruz Biotechnologies, Inc.). Similar observations (data not shown) were made using another anti-GRK6 antiserum
(Stoffel et al., 1994). Note that GRK6 is also expressed in large cholinergic striatal cells, which do not express DARPP-32, but can be labeled
with anti-choline acetyltransferase antibody (data not shown). Scale bar is equal to 50 m.
marker cassette also flanked by loxP sites (Figure 1A). gra as well as dorsal and ventral striatum (Erdtmann-
Vourliotis et al., 2001). The expression level of GRK6The floxed selection marker genes were removed in vivo
by breeding a heterozygote mouse bearing the targeted mRNA in the striatum was found to be higher than that
of other GRKs (GRK2, GRK3, and GRK5), suggestingallele with a mouse carrying a CMV-Cre transgene. A
pup bearing a deletion of both cassettes, leaving an that GRK6 might be a predominant receptor kinase in
this brain area (Erdtmann-Vourliotis et al., 2001). A de-inactivated GRK6 gene and no selection marker genes,
was identified and used to generate the colony of GRK6 tailed investigation of the expression pattern of GRK6
protein using immunohistochemistry revealed expres-knockout (GRK6-KO) mice used here. Deletion of exons
3 through 9 leads to a GRK6 that lacks most of the sion of this kinase in the majority of cells in both dorsal
and ventral striatum (Figure 1D). Particularly, GRK6 pro-amino-terminal RGS-like domain as well as half of the
conserved catalytic domain elements (Figure 1A; Hanks tein was found in the same neuronal population that
expresses DARPP-32 (dopamine- and cyclic AMP-regu-et al., 1988). Beyond the deletion, exon 10 is out of frame
relative to exon 2, so that there is little chance of any lated phosphoprotein, apparent molecular weight of
32,000 Da), a molecule involved in dopaminergic signal-active protein fragments being produced. Animal geno-
typing was performed using triplex PCR (Figure 1B) and ing mediated by both D1-like and D2-like dopamine re-
ceptors, and a phenotypic marker of the medium-sizewas confirmed by Southern blotting (data not shown)
and by analysis of GRK6 protein levels in membranes spiny GABA neurons of the mammalian striatum (Figure
1D; Greengard, 2001). These neurons represent a majorprepared from brainstem (Figure 1C) and striatum (data
not shown). striatal cell group that receive dopaminergic input, ex-
press varying levels of both D1-like and D2-like dopa-
mine receptors (Le Moine et al., 1991; Aizman et al.,Immunohistochemical Localization of GRK6
in Striatal Cells 2000; Aubert et al., 2000), and are believed to be critical
to cellular mechanisms of addiction (Nestler, 2001; Hy-Previous histological examinations have shown that
GRK6 mRNA is expressed in many brain regions, includ- man and Malenka, 2001; Laakso et al., 2002). In addition,
dense expression of GRK6 protein was detected in aing primary dopaminergic areas, such as substantia ni-
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Figure 2. Cocaine Supersensitivity in GRK6 Mutant Mice
(A) Locomotor response of GRK6 mutant (wt, n  24; GRK6 heterozygous, n  21; GRK6-KO, n  15) mice to cocaine (20 mg/kg, i.p.)
administration. GRK6 heterozygous and GRK6-KO mice are significantly different from wt controls in responses to cocaine. p  0.001, two-
way analysis of variance (ANOVA). Cocaine-induced locomotion at the time of the peak effect (10 min after injection) was 184% and 185%
in GRK6 heterozygous and GRK6-KO mice versus wt controls, respectively.
(B) Dose-response curve of the effect of cocaine (10–30 mg/kg, i.p.) on horizontal activity of GRK6-KO, heterozygous, and wt mice (n  8–24
per group). Both GRK6 heterozygous and GRK6-KO mice are significantly different from wt controls in responses to cocaine. p  0.001, two-
way ANOVA. Symbols are the same as in (A).
(C) Cocaine sensitization in GRK6-KO mice. Mice (wt, n  16; GRK6-KO, n  14) were injected daily with cocaine (20 mg/kg, i.p.) for 5 days,
and 48 hr after the last injection animals were challenged with the same dose of the drug. Locomotor activity measurements were performed
on days 1 (top left) and 7 (top right). Two-way ANOVA revealed a significant difference (p  0.001) between responses of wt mice in Day 7
versus Day 1, but no such difference was observed in GRK6-KO mice. In addition, responses in sensitized wt mice (Day 7) were not different
from that of GRK6-KO mice either in Day 1 or Day 7. The accumulated distance traveled by mice in the 90 min period after cocaine administration
on days 1 and 7 are shown in the lower panel. **p  0.01; ***p  0.001 versus wt littermates for the first day group, Student’s t test.
Analysis of accumulated distances over 15 min, 30 min, or 60 min after cocaine administration reveals a significant difference (p  0.001)
between wt and GRK6-KO mice in Day 1 at any period analyzed, but no such differences were observed between sensitized wt and GRK6-
KO mice in Days 1 or 7. In sensitized GRK6-KO mice (Day 7), locomotor responses to cocaine were not enhanced versus that in Day 1 when
30 min, 60 min, or 90 min periods after injection were analyzed. However, analysis of first 15 min period after cocaine revealed a moderate
increase in total distance traveled by GRK6-KO mice in Day 7 versus Day 1 (GRK6-KO, Day 1, 3786  459 cm/15 min; Day 7, 5386  571
cm/15 min, p  0.05, Student’s t test; for comparison, distance traveled by wt mice, Day 1, 1686  252 cm/15 min; Day 7, 4077  443 cm/
15 min, p  0.001, Student’s t test).
population of large-sized aspiny cholinergic interneu- duced lymphocyte chemotaxis (Fong et al., 2002). In
locomotor activity tests, unchallenged knockout micerons, which represent another major group of dopamino-
ceptive striatal cells expressing predominantly D2 dopa- were not different from wild-type (wt) littermates either
in horizontal (Figures 2A and 2B) or vertical activities,mine receptors (Le Moine et al., 1991; Di Chiara et al.,
1994; Aubert et al., 2000). Thus, the prominent expres- or stereotypy (data not shown). However, acute adminis-
tration of cocaine (20 mg/kg, i.p.) resulted in a markedlysion of GRK6 in the major cell groups known to express
both D1-like and D2-like receptors suggests that this enhanced locomotor response in GRK6 mutant mice
(Figures 2A and 2B). In this paradigm, the GRK6-KOkinase could be involved in the regulation of dopamine
receptor signaling. mice exhibited a more pronounced and longer lasting
locomotor activation, as measured by horizontal (Fig-
ures 2A and 2B) activity in response to cocaine (10–30Behavioral Supersensitivity to Psychostimulants
in GRK6 Mutant Mice mg/kg, i.p.) than did wild-type littermate mice. Similarly,
analysis of vertical activity and stereotypy score showedHeterozygote and homozygote GRK6-KO mice are via-
ble and present no gross anatomical or behavioral ab- the same dose-dependent enhancement of responses
to cocaine in GRK6 mutant mice (data not shown). Inter-normalities, although GRK6-KO mice demonstrate re-
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estingly, the mice heterozygous for GRK6 deletion were
as responsive to cocaine as GRK6 “null” mice (Figures
2A and 2B), suggesting that even minor changes in
GRK6 levels or activity may result in significant behav-
ioral alterations. The degree of activation induced by
cocaine (20 mg/kg, i.p.) in both heterozygous and knock-
out mice was substantially higher, not only relative to
littermate wild-type mice, but also relative to mice of
both parental strains (C57BL/6J and 129/SvJ) used to
generate the mutants (data not shown).
Repeated administration of cocaine is known to result
in a progressive enhancement of psychomotor re-
sponses. This phenomenon, termed “behavioral sensiti-
zation” or “reverse tolerance,” is believed to relate to
neuronal adaptations associated with drug addiction
(Robinson and Berridge, 1993; Nestler and Aghajanian,
1997; Hyman and Malenka, 2001). In experimental ani-
mals, it is often modeled by analyzing locomotor re-
sponses to repeated intermittent treatments with the
same dose of cocaine (Wise and Rompre, 1989; Rob-
inson and Berridge, 1993; Nestler and Aghajanian, 1997;
Wang et al., 1997; Xu et al., 2000; Nestler, 2001; Hyman
and Malenka, 2001). To test if the development of sensiti-
zation is affected by the lack of GRK6, such a cocaine-
sensitization paradigm was employed in wild-type and
GRK6-KO mice (Wang et al., 1997; Xu et al., 2000). Mice
received daily injections of cocaine for 5 consecutive
days and were tested for their responses to this drug on
the seventh day. Compared to the first day of treatment,
wild-type animals exhibited enhanced locomotor re-
sponses (2-fold) to cocaine on day 7, indicative of
sensitization (Figure 2C). By contrast, GRK6-KO animals
were as responsive to cocaine on the first day as were
wild-type mice following the sensitization protocol (Fig-
ure 2C). As might be expected from their initial exagger- Figure 3. Enhanced Locomotor Effects of d-Amphetamine and
-Phenylethylamine in GRK6 Mutant Miceated response to cocaine, GRK6-KO mice showed little
further sensitization of the locomotor response following (A) Time course of horizontal locomotor response of wt (n  10) and
GRK6 mutant (GRK6 heterozygous, n  15; GRK6-KO, n  9) inthis sensitization regimen. In fact, analysis of total dis-
response to d-amphetamine (3 mg/kg, i.p.). GRK6 heterozygoustance traveled for 90 min did not reveal significant differ-
and GRK6-KO mice are significantly different from wt controls inences between day 1 and day 7 (Figure 2C). Nonethe-
responses to d-amphetamine. p  0.001, two-way ANOVA.
less, in the first 15 min after cocaine administration, (B) Time course of horizontal locomotor response of wt (n  6) and
sensitized GRK6-KO mice did exhibit a slightly en- GRK6 mutant (GRK6 heterozygous, n  11; GRK6-KO, n  6) mice
hanced response (Figure 2C, legend), suggesting that in response to -phenylethylamine (50 mg/kg, i.p.). GRK6 heterozy-
a further sensitization to cocaine can still be developed gous and GRK6-KO mice are significantly different from wt controls
in responses to -phenylethylamine. p  0.001, two-way ANOVA.in these mice.
It is well established that the locomotor stimulating
action of cocaine is mediated by the blockade of the
it is believed that -phenylethylamine primarily acts asdopamine transporter (DAT), resulting in elevation of
an “endogenous amphetamine” via DAT-mediated ef-extracellular dopamine in the striatum and related brain
flux of dopamine from intraneuronal stores to extracellu-areas (Wise and Rompre 1989; Robinson and Berridge,
lar spaces (Janssen et al., 1999). Accordingly, in vivo1993; Gainetdinov et al., 2002). Another psychostimulant
microdialysis experiments revealed that -phenylethy-known to markedly enhance central dopaminergic trans-
lamine (50 mg/kg, i.p.) induced potent but transient ele-mission via complex interaction with the DAT is am-
vation in striatal extracellular dopamine to the samephetamine (Jones et al., 1998; Gainetdinov et al., 2002).
degree (6-fold) in both GRK6-KO and wild-type miceSimilarly to cocaine, amphetamine-induced locomotor
(data not shown). Thus, an enhanced locomotor re-activation was significantly enhanced in both GRK6 het-
sponse of GRK6 mutants to -phenylethylamine, as wellerozygous and “null” mice (Figure 3A).
as cocaine and amphetamine, is consistent with an en-Furthermore, enhanced locomotor responses were
hanced responsiveness to dopaminergic activation.observed in both heterozygous and homozygous GRK6
mutant mice when the endogenous “trace amine”
Neurochemical Characterization of Dopamine-phenylethylamine (Janssen et al., 1999; Borowsky et
Function in GRK6-KO Miceal., 2001) was administered (Figure 3B). While the func-
Behavioral supersensitivity to psychostimulants couldtions and mechanism of the stimulant action of -phe-
be explained either by alterations in presynaptic dopa-nylethylamine have not been fully determined (Janssen
et al., 1999; Borowsky et al., 2001; Premont et al., 2001), minergic function in these mice leading to augmented
Role of GRKs in the Responsiveness to Cocaine
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drug-evoked extracellular dopamine levels or by altered
postsynaptic receptor responsiveness to the same level
of dopamine. To test the status of striatal presynaptic
dopaminergic transmission in mutant mice, we as-
sessed the function of the dopamine system using a set
of neurochemical approaches (Figure 4; Wang et al.,
1997; Xu et al., 2000). GRK6-KO mice were not different
from wild-type controls in any of the neurochemical pa-
rameters examined. In particular, dopamine turnover
and storage (tissue dopamine and dopamine metabolite
content), dopamine re-uptake by DAT (synaptosomal
dopamine uptake rates), and dopamine release (basal
and cocaine-stimulated extracellular dopamine levels
as assessed by in vivo microdialysis) were not affected
in mutant mice (Figures 4A–4D). Thus, pronounced loco-
motor supersensitivity to psychostimulants in the GRK6




Behavioral supersensitivity to psychostimulants could
arise from increased responsiveness of postsynaptic
dopamine receptors. In the case of GRK6-deficient
mice, this could result from the upregulation of recep-
tors, increased affinity for endogenous agonist, and/or
enhanced coupling to G proteins. To assess the receptor
levels and agonist binding parameters of striatal D1-
like and D2-like dopamine receptors, specific antagonist
radioligand binding to striatal membranes from wild-
type and GRK6 mutant animals was performed, and the
ability of dopamine to compete with antagonist binding
was assessed. Data were fitted according to a two-site
model (Figure 5). It has been appreciated for many years
that G protein-coupled receptors, including dopamine
receptors, exist in two affinity states, and that the pro-
portion of receptors in the high-affinity state versus low-
affinity state, or the relative affinity of these states for
agonists, reflect the coupling of the receptor to down-
stream G proteins (Kent et al., 1980; De Lean et al.,
1982). No changes were found in the total levels of D1
dopamine receptor, proportions in high and low agonist
affinity states, or the affinity for dopamine between wild-
type and GRK6-deficient mice striatal membranes (Fig-
ure 5A). In contrast, the affinity of dopamine for D2 re-
ceptors in the high agonist affinity state was increased
in heterozygous (3-fold) and knockout (4-fold) mice (Khigh
[nM]: wt, 15.0  4.4; heterozygote, 4.9 1.1*; KO, 4.1 
1.2*; *p  0.05, one-way ANOVA followed by Newman-
Keuls test), without changes in total receptor levels (Fig-
ure 5B). These data suggest that the absence or de-
crease in GRK6 levels leads to enhanced coupling of
striatal D2-like receptors, but little or no change in D1-
like receptors (Kent et al., 1980; De Lean et al., 1982).
To assess potential changes in basal dopamine recep-Figure 4. Analyses of Presynaptic Dopamine Function in Wild-Type
tor sensitivity in the absense of GRK6, an analysis ofand GRK6-KO Mice
dopamine receptor coupling to G proteins was per-(A) Striatal tissue levels of dopamine, 5-HT, and their metabolites
in GRK6-KO and wt littermate mice measured by HPLC-EC (wt, n 
5; GRK6-KO, n  7).
(B) [3H]dopamine uptake in striatal synaptosomes from GRK6-KO
and wt mice (wt, n  4; GRK6-KO, n  4). dopamine level in the striatum of freely moving mice measured using
(C) Extracellular dopamine levels in the striatum of freely moving conventional microdialysis. Data are presented as a percentage of
mice measured using quantitative low perfusion rate microdialysis the average level of dopamine measured in at least three samples
(wt, n  6; GRK6-KO, n  9). collected before the drug administration. (Saline, wt, n  5; GRK6-
(D) Effect of saline and cocaine (20 mg/kg, i.p.) on extracellular KO, n  4; Cocaine, wt, n  7; GRK6-KO, n  6).
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Figure 5. Binding Parameters of D1 and D2 Dopamine Receptors in the Striatum of GRK6 Mutant Mice Measured in Competition Binding
Assay
D1 receptor binding (A) was assessed using [3H]SCH23390 (n  4 per genotype) and D2 receptor binding (B) using [3H]raclopride (n  6 per
genotype) as antagonist radioligands, respectively. Dopamine was used as a competing agonist at 24 concentrations. Under the present
conditions no alterations in D1 dopamine receptor characteristics were observed (Bound [fmol/mg]: wt, 688  18; heterozygote, 730  42;
KO, 741  46; Khigh [nM]: wt, 235  70; heterozygote, 334  69; KO, 303  55; Klow [M]: wt, 15.8  1.5; heterozygote, 17.2  1.1; KO, 16.7 
0.2; Khigh/Klow [%]: wt, 32/68; heterozygote, 37/63; KO, 36/64). Properties of D2-like dopamine receptors in high agonist affinity state were
significantly altered in GRK6 mutant mice (Bound [fmol/mg]: wt, 200  15; heterozygote, 188  11; KO, 191  7; Khigh [nM]: wt, 15.0  4.4;
heterozygote, 4.9  1.1*; KO, 4.1  1.2*; Klow [M]: wt, 1.47  0.36; heterozygote, 0.70  0.07; KO, 0.85  0.22; Khigh/Klow [%]: wt, 49/51;
heterozygote, 43/57; KO, 45/55). *p  0.05, one-way ANOVA followed by Newman-Keuls test.
formed using a [35S]GTPS binding assay (Gainetdinov assays contain no ATP, any membrane-associated
GRKs are presumed to be inactive during the assay, soet al., 1999; Lazareno, 1999; Newman-Tancredi et al.,
1999). The ability of D2/D3 dopamine receptor agonist, that any differences observed reflect the coupling state
of the receptors established in the intact cells. GRK6 isquinpirole, to stimulate binding of [35S]GTPS to the
Gi/Go proteins in the striatal membranes prepared from known to be membrane associated and to increase the
basal (agonist-independent) phosphorylation of severalwild-type and GRK6-KO mice was determined (Figure
6A). Striatal D2/D3 dopamine receptors are able to stim- receptors (Pitcher et al., 1998; Penn et al., 2000). This
suggests that the wild-type level of GRK6 may provideulate a higher level of [35S]GTPS binding in the GRK6-
KO mice, indicating that the lack of GRK6 leads to D2/ a basal level of D2/D3 receptor phosphorylation, as well
as agonist-stimulated phosphorylation, that is lost inD3 dopamine receptors that are more efficiently coupled
to their downstream G proteins. G protein (Gi/o/z) levels the GRK6 mutant animals, leading to higher receptor
sensitivity.in GRK6-KO mice were not altered, as assessed by
immunoblotting assay (data not shown). This suggests
that under basal conditions in the intact animals, dopa- Enhanced Locomotor Responses to Combined
Stimulation of D1-like and D2-like Dopaminemine receptors are tonically inhibited by GRK6, and the
loss or reduction of this inhibition in GRK6 mutant ani- Receptors in GRK6-KO Mice
It is well established that locomotor activation inducedmals leads directly to receptor supersensitivity (higher
coupling). by dopaminergic drugs requires stimulation of both D1-
and D2-like receptors (Walters et al., 1987; White et al.,To confirm the ability of GRK6 to regulate D2-like
dopamine receptors in a cellular system, GRK6 was 1988; Xu et al., 1997). In order to assess the impact
of GRK6 deletion on the responsiveness of dopaminecoexpressed with either D2 or D3 dopamine receptors
(D2R or D3R) in HEK293 cells, and dopamine-stimulated receptors in vivo, we compared the locomotor effects
of selective D1 and D2 dopamine receptor agonists in-[35S]GTPS binding to membranes was determined. In
agreement with in vivo observations on loss of GRK6, jected individually as well as in combination (Figure 7).
Wild-type and GRK6-KO mice received injections of sa-coexpression of GRK6 substantially impairs D2 and D3
dopamine receptor coupling to G proteins (Figures 6B line, D1-like dopamine receptor agonist SKF 81297 (3
mg/kg, i.p.), D2-like dopamine receptor agonist quinpir-and 6C). Thus, the absence and overexpression of GRK6
both have profound effects on D2-like dopamine recep- ole (2 mg/kg, i.p.), and the combination of these drugs
(Xu et al., 1997). While the locomotor-stimulating effecttor function. Interestingly, in the cell culture system, the
effect of GRK6 on the coupling of D2-like dopamine of SKF 81297 was not significantly different between
genotypes, a significant difference was found after quin-receptors is observed in membrane preparations from
cells with no prior exposure to dopamine. Because these pirole administration (Figures 7A and 7B). It is well known
Role of GRKs in the Responsiveness to Cocaine
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that the locomotor effects of D2-like agonists is bipha-
sic, with pronounced hypoactivity induced by lower
(presynaptic) doses of the drugs (Usiello et al., 2000)
and modest activation induced by higher (postsynaptic)
doses of the drugs (Van Hartesveldt, 1997; Zhuang et al.,
2001). However, in mice, unlike in rats, the stimulatory
action of D2-like agonists is barely evident (Halberda et
al., 1997; Usiello et al., 2000; Xu et al., 2000; Zhuang et
al., 2001). Accordingly, we observed a rapid and potent
inhibitory action of quinpirole on the activity of wt mice,
followed by only a slight activation (15–35 min after injec-
tion) that is far below the activity level of saline-treated
mice (Figures 7A and 7B). In GRK6-KO mice, quinpirole
(2 mg/kg, i.p.) potently inhibited locomotion in the first
5 min period after drug injection (Figure 7B), as well as
at any time period when administered at lower doses
(data not shown). However, at 2 mg/kg it was also signifi-
cantly more effective in inducing locomotor activation
(10–45 min after injection), suggesting enhanced sensi-
tivity of postsynaptic D2-like receptors (Figure 7B). Fi-
nally, mice were treated with a combination of D1 and
D2 dopamine receptor agonists (SKF 81297, 3 mg/kg,
i.p. plus quinpirole, 2 mg/kg, i.p.), and locomotor activity
was assessed (Figures 7A and 7C). It is known that in
intact mice a tonic stimulation of dopamine receptors
by endogenous dopamine and the relatively weak post-
synaptic activity of D2 dopamine agonists complicate
the clear demonstration of D1/D2 dopamine receptor
synergism in the control of locomotion (Walters et al.,
1987; Xu et al., 1997). Accordingly, we did not see a
significant enhancement of D1 agonist-induced hyperlo-
comotion by additional stimulation of D2 receptors in
both genotypes, but, importantly, a significant differ-
ence between wild-type and GRK6-KO mice was found
(Figures 7A and 7C). Thus, the lack of GRK6 in mice
results in exaggerated locomotor responses to com-
bined stimulation of D1 and D2 dopamine receptors, the
difference most likely determined by the altered respon-
siveness of postsynaptic D2-like receptors. Further-
more, in a separate experiment, pretreatment (30 min)
of mice by either D1 dopamine receptor antagonist SCH
23390 (0.1 mg/kg, i.p.) or D2 dopamine receptor antago-
nist raclopride (2 mg/kg, i.p.) was similarly effective in
both genotypes in blocking activation induced by a com-
bination of D1 and D2 agonists (data not shown), thereby
supporting the requirement for the cooperative action
of D1 and D2 receptors in the control of locomotion
(White et al., 1988; Xu et al., 1997).
Figure 6. Alterations in GRK6 Level Modulate Dopamine Receptor
Enhanced Postsynaptic ResponsivenessCoupling to G Proteins
to Dopamine Agonist in GRK6-KO Mice(A) [35S]GTPS binding to striatal membranes from mutant and wild-
type mice. [35S]GTPS binding to striatal membranes was deter- Striatal D2/D3 dopamine receptors have been localized
mined after stimulation with quinpirole. Percent stimulated both on presynaptic dopamine nerve terminals and
[35S]GTPS binding was calculated by dividing unstimulated postsynaptic striatal cells (Schwartz et al., 1993; See-
[35S]GTPS binding into each agonist-stimulated point. Nonlinear man and Van Tol, 1994; Picetti et al., 1997; Missale et
regressions were used to calculate the EC50 parameters (wt, 2.0 
al., 1998; Sibley, 1999). To assess directly postsynaptic0.5 M; GRK6-KO, 1.9 0.6 M). In the absence of agonist stimula-
tion, basal [35S]GTPS binding did not differ between genotypes.
Experiments were performed in triplicate in which wt and GRK6-
KO striatal tissue were analyzed simultaneously (n  8 per group).
p  0.001, two-way ANOVA, GRK6-KO versus wt controls. (C) [35S]GTPS binding to HEK-293 cell membranes expressing D3R/
(B) [35S]GTPS binding to HEK-293 cell membranes expressing D2R Go was determined after stimulation with dopamine. At least two
was determined after stimulation with dopamine. At least two inde- independent experiments were performed in triplicate. The same
pendent experiments were performed in triplicate. The same proce- procedure was employed for data treatments. p  0.001, two-way
dure was employed for data treatments. p 0.001, two-way ANOVA. ANOVA.
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Figure 7. Effects of D1- and D2-like Dopa-
mine Receptor Agonists on Locomotor Activ-
ity of GRK6-KO and Wild-Type Mice
GRK6-KO and wild-type mice (n  10) re-
ceived injections of saline, SKF 81297 (3 mg/
kg, i.p.), quinpirole (2 mg/kg, i.p.), and the
combination of these two drugs in consecu-
tive trials separated by 7 days.
(A) Total distance traveled by the animals for
90 min after drugs. p  0.05 versus effect of
the same treatment in wild-type mice, Stu-
dent’s t test.
(B) Time course of the effect of quinpirole (2
mg/kg, i.p.) on locomotion in GRK6-KO and
wild-type mice. p  0.001 versus wild-type
group, two-way ANOVA.
(C) Time course of the effect of combination
of D1 and D2 agonists (SKF 81297 [3 mg/kg,
i.p.] plus quinpirole [2 mg/kg, i.p.]) on the lo-
comotor activation in GRK6-KO and wild-
type mice. p  0.001 versus wild-type group,
two-way ANOVA.
dopamine receptor responsiveness in GRK6-KO mice, et al., 1995; Pitcher et al., 1998; Penn et al., 2000). GRK-
phosphorylated receptors bind to an arrestin protein,the effect of the nonselective dopamine agonist apomor-
phine was tested in dopamine-depleted mice, where no which prevents the receptor from activating more G
proteins, despite the continued binding of agonistendogenous dopamine neurotransmission was present
(Figure 8). The paradigm used was originally developed (Pitcher et al., 1998). Several GRK enzymes (GRK2,
GRK3, GRK5, and GRK6) are found in the brainto test drugs effective in Parkinson’s disease, where
profound loss of dopamine innervation occurs (Carlsson (Gainetdinov et al., 2000; Erdtmann-Vourliotis et al.,
2001), but the physiological importance and receptoret al., 1991; Carlsson, 2001). Wild-type and GRK6-KO
mice were treated with reserpine (5 mg/kg, i.p.) to de- specificity of these enzymes remain unclear. It is evident
that specificity of GPCR regulation by GRKs requiresplete intraneuronal storage of monoamines including
dopamine, and with -methyl-p-tyrosine (250 mg/kg, cellular colocalization of the proteins but may also in-
volve specificity of receptors for particular GRKs. Fur-i.p.) to inhibit dopamine synthesis. Both GRK6 mutant
and control mice were completely immobilized by this ther, GRK activity is a highly regulated process and
can be modulated by subcellular compartmentalization,treatment. Locomotion in dopamine-depleted wild-type
and mutant mice was restored by administration of the alterations in intrinsic activity, or expression levels of
the kinase (Penn et al., 2000).nonselective D1/D2 dopamine receptor agonist apo-
morphine (0.2–1 mg/kg, s.c.) (Figures 8A–8C). GRK6-KO Since there are no known general or subtype-specific
GRK antagonists, we have utilized a gene “knockout”mice showed a markedly enhanced locomotor response
to apomorphine in comparison to wild-type littermates, strategy to begin to address the physiological role of
individual GRKs (Jaber et al., 1996; Peppel et al., 1997;directly demonstrating that postsynaptic dopamine re-
ceptor responsiveness is enhanced in GRK6 mutant Gainetdinov et al., 1999). Here we report that one of the
G protein-coupled receptor kinases, GRK6, is localizedmice. Furthermore, these data suggest that a decrease
in GRK6 levels or activity could enhance the behavioral in striatal neurons receiving dopaminergic input, and
that postsynaptic D2/D3 dopamine receptors are physi-effects of dopamine agonists in situations where the
dopaminergic stimulus is limiting, such as Parkinson’s ological targets of this kinase. Furthermore, supersensi-
tivity to dopamine agonist stimulation that occurs indisease (Carlsson, 2001).
striatal neurons in the absence or reduction of GRK6
suggests that this direct regulation of D2/D3 dopamineDiscussion
receptor by GRK6 represents an important determinant
by which responses to psychostimulants or other dopa-An important mechanism for GPCR desensitization is
the uncoupling of the activated receptors from further minergic drugs can be controlled.
Interestingly, cellular experiments with coexpressedstimulation of their G proteins. This form of desensitiza-
tion is mediated by the phosphorylation of the activated D2-like dopamine receptors and GRK6 indicate that ele-
vated GRK6 levels can reduce dopamine receptor sig-receptor by members of the family of GRKs (Premont
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GRK3, is unlikely to be involved in the regulation of
dopaminergic receptors, since mice lacking GRK3 (Pep-
pel et al., 1997) do not demonstrate enhanced responses
to either cocaine or apomorphine (unpublished data).
GRK4 has very limited expression in the brain (Pitcher
et al., 1998; Gainetdinov et al., 2000), precluding its
involvement in dopamine receptor regulation in the
brain. Deletion of the GRK2 gene results in embryonic
lethality (Jaber et al., 1996), so the role of this GRK on
dopamine-mediated behaviors has not been fully exam-
ined. Thus, GRK6 may play a unique role in D2-like
dopamine receptor regulation.
Dopamine receptors belong to a large family of recep-
tors that are linked to their signal transduction pathways
through G proteins (Grandy and Civelli, 1992; Schwartz
et al., 1993; Seeman and Van Tol, 1994; Picetti et al.,
1997; Missale et al., 1998; Sibley, 1999). A variety of
signaling events can be regulated by dopamine recep-
tors, including adenylyl cyclase and phospholipase C
activities and various ion channels. Based on physio-
logical and pharmacological properties, dopamine re-
ceptors are defined as D1-like (D1 and D5) and D2-like
(D2, D3, D4) subfamilies of dopamine receptors (Missale
et al., 1998). Many of these subtypes (particularly be-
longing to the same subfamily) respond similarly to phar-
Figure 8. Locomotor Responses to Direct Dopamine Receptor Acti- macological agents, making it difficult to selectively
vation Are Enhanced in Dopamine-Depleted GRK6-KO Mice stimulate or block a specific receptor subtype using
To deplete brain dopamine, animals were treated with a combination pharmacological approaches (Missale et al., 1998; Sib-
of reserpine (5 mg/kg, i.p.) and -methyl-p-tyrosine (250 mg/kg, i.p.) ley, 1999). In the brain, the various receptor subtypes
as described in Experimental Procedures. display specific distributions, with D1-like receptors be-
(A) Time course of effect of apomorphine (0.5 mg/kg, s.c.) on the
ing mainly postsynaptic and D2-like receptors beinghorizontal activity (counts) of dopamine-depleted wild-type (n  11)
both pre- and postsynaptic (Picetti et al., 1997; Missaleand GRK6-KO (n 7) mice. GRK6-KO mice are significantly different
et al., 1998; Sibley, 1999). An important question arisingfrom wt controls. p  0.001, two-way ANOVA.
(B and C) Dose-response of the effect of apomorphine (0.2–1 mg/ from the present observations is what subtypes of dopa-
kg, s.c.) on the locomotion of dopamine-depleted wild-type and mine receptors are primarily regulated by GRK6. As-
mutant mice (n  6–11 per group). Note that GRK6-KO mice were sessment of binding characteristics of striatal dopamine
more affected by apomorphine both in terms of horizontal activity receptors and locomotor responses to selective ago-
counts (B) and total distance traveled (C). p  0.001 versus wild-
nists demonstrated that properties of D2-like dopaminetype group for horizontal activity counts (B) and p  0.05 for total
receptors, but not those of D1-like, are significantly af-distance traveled (C) measurements, two-way ANOVA.
fected in GRK6 mutant mice. Furthermore, D2-like dopa-
mine receptors appear to be more efficiently coupled to
naling. Further, when D3 dopamine receptor was coex- their G proteins and thereby contribute to the enhanced
pressed with GRK2 or GRK3, only a minor effect (less locomotor responses to dopaminergic stimulation in
than 15% reduction in dopamine-stimulated [35S]GTPS GRK6-KO mice. Due to lack of selectivity of the phar-
binding) was observed (data not shown). This suggests macological approaches, it is impossible at present to
that specificity of D3 dopamine receptor regulation re- discriminate between individual subtypes of D2-like do-
sides in a preference for GRK6 over other GRKs. Coex- pamine receptors responsible for these effects. Never-
pression of GRK6 also enhanced the basal (unstimulated) theless, since D4 dopamine receptor has a limited ex-
translocation of -arrestin2 to D2R or D3R, reflecting pression in the striatum (Rivera et al., 2002), the most
increased basal receptor phosphorylation (data not likely candidates would be D2 and D3 dopamine recep-
shown). Thus, in an in vitro system, GRK6 appears to tors. Direct challenge of postsynaptic dopamine recep-
induce a basal level of desensitization of D2/D3 dopa- tors using dopamine depletion approach (Carlsson et al.,
mine receptors. This is in agreement with many previous 1991) revealed that postsynaptic receptors are primarily
studies that have shown in other receptor systems that affected. However, the present data do not exclude the
membrane-associated GRK6 induces basal (activation- possibility that presynaptic D2/D3 dopamine “autore-
independent) receptor phosphorylation (Pitcher et al., ceptors,” low levels of striatal D4 dopamine receptors,
1998; Penn et al., 2000), and suggests that this basal and/or various populations of dopamine receptors in
receptor phosphorylation tone is physiologically impor- the other brain areas might also be affected in GRK6-KO
tant, at least for some dopamine receptors. mice. In addition, the widespread expression of GRK6 in
Importantly, mice lacking another member of this ki- brain suggests that nondopaminergic receptor types
nase family, GRK5, do not demonstrate such dopamin- may also be physiological targets for this kinase; de-
ergic supersensitivity, but do display exaggeration of tailed investigation will be required to establish the port-
central muscarinic cholinergic responses (Gainetdinov folio of receptors affected in GRK6 mutant mice.
It has been previously reported that supersensitivityet al., 1999). Another GRK widely expressed in the brain,
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LoxL vector with NotI and Sse8387I and ligated into those sites ofto light is present in GRK1-KO animals (Chen et al.,
the LoxC/TK-NEO vector. The long recombination arm, floxed gene1999), cardiac supersensitivity to -adrenergic stimula-
fragment, and floxed TK-NEO marker cassette were excised fromtion is present in heterozygous GRK2-KO mice (Rock-
this vector with NotI and AscI and inserted into those sites in the
man et al., 1998), supersensitivity to olfactory stimuli LoxR/DT vector to create the final targeting construct (Figure 1A).
(Peppel et al., 1997) and enhanced muscarinic choliner- Growth and selection of targeted ES cells and creation of chimeric
mice was performed essentially as described (Hogan et al., 1994).gic airway responsiveness (Walker et al., 1999) are pres-
The targeting DNA was linearized by digestion with NotI and electro-ent in GRK3-KO animals, and central muscarinic recep-
porated into AK7 ES cells. Cells were selected for growth in mediator supersensitivity is observed in GRK5-KO mice
containing 200 g/ml G418, and surviving clones were tested for(Gainetdinov et al., 1999). These observations as well
proper integration by amplification of a DNA band from the PGK
as present findings strongly suggest a generalized prin- promoter of the NEO marker gene to a region near exon 2 adjacent
ciple that abrogation of GRK-mediated receptor desen- to the targeting construct. The identity of positive clones was con-
firmed by Southern blotting of genomic DNA isolated from the cellssitization can enhance responses to both endogenous
and digested with SpeI, using a probe from adjacent to exon 2and exogenous ligands and thus may represent a poten-
(Figure 1A). A targeted cell clone with a normal karyotype was ex-tial mechanism for behavioral or physiological supersen-
panded and microinjected into day 3.5 C57BL/6J mouse blasto-sitivity.
cysts, which were then injected into the uterus of a day 2.5 pseudo-
One example of behavioral supersensitivity is chronic pregnant B6SJLF1/J mouse. Chimeric offspring were crossed with
psychostimulant-induced enhancement of dopaminer- C57BL/6J mice to generate agouti pups that carried the targeted
“lox” GRK6 gene. F1 heterozygote animals were bred with trans-gic responses (Wise and Rompre, 1989; Robinson and
genic mice bearing CMV-Cre (backcrossed to a C57Bl/6J geneticBerridge, 1993), which is believed to be associated with
background; Nagy et al., 1998) to induce deletion of the floxedchanges in several signaling molecules downstream of
cassettes. From offspring of these crosses, GRK6-KO animals wereDA receptors (Nestler and Aghajanian, 1997; Hyman and
obtained, in which both the exon 3–9 cassette and the TK-NEO
Malenka, 2001; Nestler, 2001; Laakso et al., 2002). The marker gene cassettes were deleted (i.e., the gene is inactive). Geno-
present observatons raise the possibility that GRK6- typing was routinely performed on tail tip DNA using a PCR method
utilizing three primers to simultaneously detect the wild-type andregulated desensitization of dopamine receptors might
mutant loci (Figure 1B).represent a novel component in the development of
such sensitization. The observation that single-allele in-
Western Blotsactivation of GRK6 in mice produces a phenotype identi-
Mouse brain regions were dissected on ice and immediately frozencal to the complete knockout of the gene raises the
in liquid nitrogen. Crude membranes were prepared from mouse
possibility that even subtle allelic variations in the human brain regions by polytron homogenization in buffer (20 mM Tris, 1
GRK6 gene or drug-induced alterations in GRK6 activity mM EDTA, 100 mM NaCl [pH 7.4]) followed by centrifugation at
might contribute to individual sensitivity to psychostim- 200 	 g for 2 min and then at 21,000 	 g for 30 min. Aliquots
(60 g) of each sample were solubilized by addition of SDS-PAGEulants and/or other drugs affecting dopaminergic func-
sample buffer and separated by 10% SDS-PAGE. Transferred pro-tion. Furthermore, since supersensitivity of DA receptors
teins were blotted with polyclonal anti-GRK6 (Stoffel et al., 1994) andhas been implicated in the pathogenesis or adverse
visualized using enhanced chemiluminescent development (ECL,
reactions associated with treatment of schizophrenia, Amersham, Piscataway, NJ).
Tourette Syndrome, and Parkinson’s disease (Pandey
et al., 1977; Kirkpatrick et al., 1992; Jenner and Marsden, Immunohistochemistry
1987; Singer, 1994), a role for GRK6-mediated DA recep- Wild-type or GRK6-KO mice (n  3) were anesthetized with chloral
hydrate (400 mg/kg, i.p.) and perfused transcardially with 0.9% sa-tor regulation in these conditions would be of interest
line, followed by 4% paraformaldehyde in 0.1 M borax buffer (pHto consider. Particularly, a pharmacological strategy
9.5 at 4
C). Brains were post-fixed for 1–3 days and cryoprotectedbased on blockade of GRK6-mediated desensitization
in 10% sucrose. Free floating coronal or saggital sections of 25 m
may be effective in enhancing the potency of the low were incubated 32 hr at 4
C with a mixture of antibodies against
levels of residual dopamine found in parkinsonian pa- DARPP-32 (mouse, 1:5000, D97520, BD Transduction Laboratories)
tients, or augmentating the efficacy of L-DOPA replace- and GRK6 (rabbit, 1:50, sc-566, Santa Cruz Biotechnologies, Inc.).
The second immunoreaction step was performed by incubation (1ment therapy.
hr at room temperature) with each of the following antibodies: fluo-
rescein-isothiocyanate-labeled goat anti-rabbit IgG and Texas Red-Experimental Procedures
labeled goat anti-mouse IgG (Vector Laboratories). Slides were
viewed on a laser scanning Zeiss confocal microscope (LSM-510)Targeted Deletion of the Mouse GRK6 Locus
using the Roper Scientific Cooled CCD digital camera (Coolsnap-The three Triple-Lox vectors described for the GRK5 knockout
FX, BioVision Technologies, Inc., PA) and the IPLab software for(Gainetdinov et al., 1999) were modified as follows. The LoxL vector
Windows v3.0 for image processing (BioVision Technologies, Inc).was modified to have a new multiple cloning site containing NotI
Images were acquired separately in each channel (dual scan mode)and NheI sites, a loxP element, and SpeI, XhoI, and Sse8387I sites.
to eliminate the possibility of signal bleed-over from one channelThe LoxR/DT vector was modified to contain a multiple cloning
to the other.region containing NotI, AscI, XbaI, XhoI, EcoRI, and PmeI sites.
Phage  carrying fragments of the mouse GRK6 gene from the
129/SVJ strain were obtained and sequenced as described (Premont Animal Treatment/Drugs/Behavior
3- to 4-month-old littermate wild-type and GRK6 mutant miceet al., 1999). The 2.75 kb XbaI-NheI fragment containing exons 3
through 9 (the gene fragment to be flanked by loxP sites, or floxed) (C57BL/6J	 129/SvJ) were used in these experiments. In all experi-
ments, wild-type littermates served as controls for mutant mice,and the 6.8 kb NheI-NotI fragment containing exons 10 through 15
(the long recombination arm) were ligated into the SpeI and NotI- and all the genotypes were evaluated concurrently. Horizontal, verti-
cal, and stereotypical activities of littermate wild-type, heretozygote,NheI sites of the LoxL vector, respectively. The 1.3 kb XbaI gene
fragment containing exon 2 (the short recombination arm) was pre- and knockout mice of both genders were measured in an Omnitech
Digiscan activity monitor (42 cm2). Locomotor activity was measuredpared by partial digestion and ligated into the XbaI site in the LoxR/
DT vector. The cassette containing the long recombination arm, at 5 min intervals and cumulative counts were taken for data analysis
(Wang et al., 1997; Xu et al., 2000). To evaluate the effects of cocaine,loxP site, and gene fragment to be floxed were excised from the
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amphetamine, and -phenylethylamine on locomotor behavior, mice 7.4), 120 mM NaCl, and 1 mM EDTA, and centrifuged for 20 min at
40,000 	 g at 4
C. Pellets were resuspended in the same buffer andwere placed in activity monitor, 30–60 min later they were injected
with drugs or vehicle i.p., and locomotor activity was monitored for incubated for 15 min at 37
C to facilitate the removal of endogenous
DA. After incubation, membranes were centrifuged for 10 min atthe following 90 min. In cocaine sensitization (Wang et al., 1997; Xu
et al., 2000) experiments, mice were treated chronically with cocaine 40,000 	 g at 4
C, resuspended in ice-cold buffer, and centrifuged
again. The resulting pellet was then homogenized in the binding(20 mg/kg, i.p.) for 5 days and their responses to challenging dose
of cocaine were analyzed at day 7. To analyze the effect of direct buffer containing 50 mM Tris-HCl (pH 7.4), 120 mM NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2, and 0.1% ascorbic acid. D1 receptordopamine agonist in dopamine-depleted mice (Carlsson et al.,
1991), animals were pretreated with a combination of reserpine (5 binding was assessed using 1 nM [3H]SCH23390 in the presence of
100 nM ketanserin (to prevent binding to 5-HT2A receptors), andmg/kg, i.p. 20 hr before the experiment) and -methyl-p-tyrosine
(250 mg/kg, i.p., 1 hr before the experiment). This treatment resulted D2 receptor binding was assessed using 3 nM [3H]raclopride (New
England Nuclear/Perkin Elmer Life Sciences). Dopamine was usedin depletion of striatal dopamine to less than 0.75% in both wild-
type and GRK6-KO mice (data not shown). Mice were completely as the competing agonist (24 concentration points in duplicate, from
108.5 to 102 M for D1 receptor, and from 109.5 to 103 M for D2immobilized by this treatment. Dopamine-depleted mice were
treated with vehicle or D1/D2 dopamine receptor agonist apomor- receptor). Protein concentration was measured using the Lowry
assay, and 40 g and 60 g of membrane protein in 200 l reactionphine (0.2–1 mg/kg, s.c.), and locomotor activity was immediately
analyzed as described above. A nonrandomized repeated measures volume was used for each point for D1 and D2 receptor binding,
respectively. Binding reaction was incubated for 45 min at roomdesign was employed to assess the locomotor effects of selective
and combined stimulation of D1-like and D2-like dopamine recep- temperature, and bound ligand was separated from free by rapid
filtration onto Whatman GF/C filters washed with ice-cold Tris buffer.tors (Xu et al., 1997). Once a week each mouse was habituated to
locomotor activity chambers (30 min) and received saline, R-()- Two-site competition curves were fitted individually for every animal
(striata from two animals were pooled for each “n” in D2 bindingSKF-81297 (SKF 81297, 3 mg/kg, i.p.), quinpirole (2 mg/kg, i.p.), or
combination of SKF 81297 (3 mg/kg, i.p.) plus quinpirole (2 mg/kg, assay) by nonlinear regression using GraphPad Prism software
(GraphPad Software Inc., San Diego, CA). Values of KHigh, KLow, frac-i.p.), consecutively. In all other experiments (with exception of the
sensitization paradigm), each animal received only a single injection tion of receptors in KHigh, and the amount of specifically bound ra-
dioligand generated by nonlinear regression algorithm were sub-with a tested drug. All the data presented in this study are expressed
as means  SEM. jected to statistical analysis. Statistical significances were assessed
with one-way ANOVA followed by Newman-Keuls test for post hoc
analyses.Neurochemical Assessments
For monoamine analyses, brain regions were dissected and mono-
Acknowledgmentsamines extracted and analyzed for levels of dopamine, serotonin
(5-hydroxytryptamine, 5-HT), and metabolites 3,4-dihydroxyphenyl-
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